PHAR ▼ -1.8% - Pharming Group N.V.
$PHAR - Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026
14-OCT-2026 02:00 AM ET
Share this post
More filings for $PHAR
PHAR ▲ +6.3% - Pharming Group N.V.Oct 27, 2026PHAR ▼ -1.0% - Pharming Group N.V.Oct 22, 2026PHAR ▲ +0.6% - Pharming Group N.V.Sep 29, 2026
View full $PHAR filing history →💬 Comments
Loading comments…
Leave a comment